Synergistic Effect of Afatinib with Su11274 in Non-Small Cell Lung Cancer Cells Resistant to Gefitinib or Erlotinib

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Chen, Gang ^a,b   Noor, Alfiah ^b   Kronenberger, Peter ^b,c   Teugels, Erik ^b   Umelo, Ijeoma Adaku ^b   De Grève, Jacques ^b  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c Erasmushogeschool Brussel   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; CASPASE 3; CASPASE 7; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA; STAT PROTEIN;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FLUOROMETRY; HUMANS; INDOLES; MICROSCOPY, FLUORESCENCE; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SPECTROPHOTOMETRY; SULFONAMIDES;

EID: 84875083480     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059708     Document Type: Article

References (61)

1. Lin WH, Song JS, Chang TY, Chang CY, Fu YN, et al. (2008) A cell-based high-throughput screen for epidermal growth factor receptor pathway inhibitors. Anal Biochem 377: 89-94.
2. Han W, Pan H, Chen Y, Sun J, Wang Y, et al. (2011) EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS One 6: e18691.
3. Mendelsohn J, Baselga J, (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21: 2787-2799.
4. Zhou S, Ren S, Yan L, Zhang L, Tang L, et al. (2009) Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer. Respirology 14: 709-715.
5. Felip E, Rojo F, Reck M, Heller A, Klughammer B, et al. (2008) A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin Cancer Res 14: 3867-3874.
6. Milton DT, Azzoli CG, Heelan RT, Venkatraman E, Gomez JE, et al. (2006) A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. Cancer 107: 1034-1041.
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132.
8. Rosell R, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. (2011) Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. J Clin Oncol 29: suppl; abstr 7503.
9. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, et al. (2011) Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29: 2866-2874.
10. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957.
11. Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, et al. (2008) Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 26: 2450-2456.
12. Yap TA, Vidal L, Adam J, Stephens P, Spicer J, et al. (2010) Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 28: 3965-3972.
13. Spicer JF, Rudman SM (2010) EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. Target Oncol.
14. Minkovsky N, Berezov A, (2008) BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr Opin Investig Drugs 9: 1336-1346.
15. Eskens FA, Mom CH, Planting AS, Gietema JA, Amelsberg A, et al. (2008) A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer 98: 80-85.
16. Schutze C, Dorfler A, Eicheler W, Zips D, Hering S, et al. (2007) Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma. Strahlenther Onkol 183: 256-264.
17. Yang JC-H, Schuler MH, Yamamoto N, O'Byrne KJ, Hirsh V, et al. (2012) LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol 30: suppl; abstr LBA7500.
18. Griffin S, Walker S, Sculpher M, White S, Erhorn S, et al. (2009) Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck. Health Technol Assess 13Suppl 1: 49-54.
19. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-578.
20. Hanna N, Lilenbaum R, Ansari R, Lynch T, Govindan R, et al. (2006) Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 24: 5253-5258.
21. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, et al. (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373: 1525-1531.
22. Burnett JC, Rossi JJ, Tiemann K (2011) Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J.
23. Hickerson RP, Leachman SA, Pho LN, Gonzalez-Gonzalez E, Smith FJ, et al. (2011) Development of quantitative molecular clinical end points for siRNA clinical trials. J Invest Dermatol 131: 1029-1036.
24. Burnett JC, Rossi JJ, Tiemann K, (2011) Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J 6: 1130-1146.
25. Sordella R, Bell DW, Haber DA, Settleman J, (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167.
26. Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borras AM, et al. (2006) Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest 116: 2695-2706.
27. Rothenberg SM, Engelman JA, Le S, Riese DJ, 2nd, Haber DA, et al (2008) Modeling oncogene addiction using RNA interference. Proc Natl Acad Sci U S A 105: 12480-12484.
28. Tang Z, Du R, Jiang S, Wu C, Barkauskas DS, et al. (2008) Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer 99: 911-922.
29. Yamanaka S, Gu Z, Sato M, Fujisaki R, Inomata K, et al. (2008) siRNA targeting against EGFR, a promising candidate for a novel therapeutic application to lung adenocarcinoma. Pathobiology 75: 2-8.
30. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
31. Bean J, Brennan C, Shih JY, Riely G, Viale A, et al. (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104: 20932-20937.
32. Beau-Faller M, Ruppert AM, Voegeli AC, Neuville A, Meyer N, et al. (2008) MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naive cohort. J Thorac Oncol 3: 331-339.
33. Guo A, Villen J, Kornhauser J, Lee KA, Stokes MP, et al. (2008) Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A 105: 692-697.
34. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, et al. (2005) Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 65: 1479-1488.
35. Cipriani NA, Abidoye OO, Vokes E, Salgia R, (2009) MET as a target for treatment of chest tumors. Lung Cancer 63: 169-179.
36. Deheuninck J, Foveau B, Goormachtigh G, Leroy C, Ji Z, et al. (2008) Caspase cleavage of the MET receptor generates an HGF interfering fragment. Biochem Biophys Res Commun 367: 573-577.
37. Siegfried JM, Weissfeld LA, Luketich JD, Weyant RJ, Gubish CT, et al. (1998) The clinical significance of hepatocyte growth factor for non-small cell lung cancer. Ann Thorac Surg 66: 1915-1918.
38. Sattler M, Reddy MM, Hasina R, Gangadhar T, Salgia R, (2011) The role of the c-Met pathway in lung cancer and the potential for targeted therapy. Ther Adv Med Oncol 3: 171-184.
39. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, et al. (2004) Rational siRNA design for RNA interference. Nat Biotechnol 22: 326-330.
40. Ui-Tei K, Naito Y, Takahashi F, Haraguchi T, Ohki-Hamazaki H, et al. (2004) Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res 32: 936-948.
41. Jagla B, Aulner N, Kelly PD, Song D, Volchuk A, et al. (2005) Sequence characteristics of functional siRNAs. RNA 11: 864-872.
42. Chen G, Kronenberger P, Teugels E, Umelo IA, De Greve J (2012) Effect of siRNAs targeting T790M mutation and wild type EGFR in non-small cell lung cancer cell line resistant to gefitinib or erlotinib. Biochem Biophys Res Commun.
43. Chen G, Kronenberger P, Umelo IA, Teugels E, De Grève J, (2010) Quantification of epidermal growth factor receptor T790M mutant transcripts in lung cancer cells by real-time reverse transcriptase-quantitative polymerase chain reaction. Anal Biochem 398: 266-268.
44. Chen G, Kronenberger P, Teugels E, De Grève J, (2011) Influence of RT-qPCR primer position on EGFR interference efficacy in lung cancer cells. Biol Proced Online 13: 1.
45. Chen G, Kronenberger P, Teugels E, Adaku Umelo I, De Greve J, (2012) Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Med 10: 28.
46. Giovannetti E, Lemos C, Tekle C, Smid K, Nannizzi S, et al. (2008) Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol 73: 1290-1300.
47. Janmaat ML, Rodriguez JA, Gallegos-Ruiz M, Kruyt FA, Giaccone G, (2006) Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int J Cancer 118: 209-214.
48. Wang L, Xiang S, Williams KA, Dong H, Bai W, et al. (2012) Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells. PLoS One 7: e44265.
49. Simoens C, Vermorken JB, Korst AE, Pauwels B, De Pooter CM, et al. (2006) Cell cycle effects of vinflunine, the most recent promising Vinca alkaloid, and its interaction with radiation, in vitro. Cancer Chemother Pharmacol 58: 210-218.
50. Alemany R, Ruan S, Kataoka M, Koch PE, Mukhopadhyay T, et al. (1996) Growth inhibitory effect of anti-K-ras adenovirus on lung cancer cells. Cancer Gene Ther 3: 296-301.
51. Chenau J, Michelland S, de Fraipont F, Josserand V, Coll JL, et al. (2009) The cell line secretome, a suitable tool for investigating proteins released in vivo by tumors: application to the study of p53-modulated proteins secreted in lung cancer cells. J Proteome Res 8: 4579-4591.
52. Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, et al. (2009) PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 69: 3256-3261.
53. Choi YJ, Rho JK, Jeon BS, Choi SJ, Park SC, et al. (2010) Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors. Cancer Chemother Pharmacol 66: 381-388.
54. Shimamura T, Lowell AM, Engelman JA, Shapiro GI, (2005) Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res 65: 6401-6408.
55. Zucali PA, Ruiz MG, Giovannetti E, Destro A, Varella-Garcia M, et al. (2008) Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Ann Oncol 19: 1605-1612.
56. Onozato R, Kosaka T, Kuwano H, Sekido Y, Yatabe Y, et al. (2009) Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol 4: 5-11.
57. Chou TC, (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681.
58. Zhang YW, Staal B, Essenburg C, Su Y, Kang L, et al. (2010) MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res 70: 6880-6890.
59. Puri N, Salgia R, (2008) Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J Carcinog 7: 9.
60. Tabara K, Kanda R, Sonoda K, Kubo T, Murakami Y, et al. (2012) Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells. PLoS One 7: e41017.
61. Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, et al. (2012) HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR mutant lung cancers that lack the second-site EGFR T790M mutation. Cancer Discov.